Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2011-09-28 / Clin. Dev. Immunol. 2011;2011:249281A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2011-09-17 / Cancer Immunol. Immunother. 2012 Mar;61(3):373-84Current immunotherapeutic approaches in pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2011-09-14 / Clin. Dev. Immunol. 2011;2011:267539Immunotherapy in human glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-08-31 / Rev. Neurol. (Paris) 2011 Oct;167(10):668-72HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy
/in Breast Cancer, Dendritic Cells, International Publications /von 2011-08-16 / J. Mol. Med. 2011 Dec;89(12):1231-40Immunotherapy for prostate cancer: biology and therapeutic approaches
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-08-08 / J. Clin. Oncol. 2011 Sep;29(27):3677-85Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells
/in Acute Leukemia, Dendritic Cells, International Publications /von 2011-08-04 / Ger Med Sci 2011;9:Doc18Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
/in Dendritic Cells, International Publications /von 2011-08-01 / Immunol. Res. 2011 Aug;50(2-3):235-47Antigen-specific immunity and tumor inflammation after vaccination with BPX-101, a drug-activated dendritic cell vaccine for metastatic castration-resistant prostate cancer (mCRPC).
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-07-31 / J Clin Oncol 29: 2011 (suppl 7; abstr 176)IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de